Dr Reddy’s launches generic chemotherapy drug in the US

Pharma manufacturer Dr. Reddy’s Laboratories said it launched a generic version of chemotherapy drug drug Alkeran.

The drug is used for palliative — or relief-oriented — treatment of multiple myeloma and epithelial carcinoma of the ovary.

The Alkeran brand and generic had U.S. sales of approximately $107 million MAT for the most recent twelve months ending in October 2017, Dr Reddy’s said.

The product, Melphalan Hydrochloride Injection, is a therapeutic equivalent generic version of Alkeran (melphalan hydrochloride) for injection in the United States.

It will be sold in a carton containing one singledose clear glass vial of freeze-dried melphalan hydrochloride equivalent to 50 mg melphalan and one 10 mL clear glass vial of sterile diluent, it said



Popular posts from this blog

EMA Recommends Extension of Indications for Ramucirumab

Dr. Hootie Warren takes helm of Fred Hutch Global Oncology

Bristol-Myers Squibb and Clovis Oncology Announce a Broad Clinical Collaboration to Evaluate Combination of Opdivo (Nivolumab) and Rubraca® (Rucaparib) in Phase 2 and Pivotal Phase 3 Clinical Trials in Multiple Tumor Types